Catriona Yale Sells 1,633 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 1,633 shares of the company's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total transaction of $89,553.72. Following the completion of the transaction, the insider now directly owns 90,598 shares of the company's stock, valued at approximately $4,968,394.32. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Monday, June 16th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.23, for a total value of $542,300.00.
• On Tuesday, June 10th, Catriona Yale sold 2,803 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $151,362.00.
• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $39.30, for a total value of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The stock was sold at an average price of $37.91, for a total transaction of $343,957.43.

Akero Therapeutics Stock Performance

Shares of AKRO traded down $0.17 during mid-day trading on Monday, hitting $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. The firm has a market cap of $4.31 billion, a P/E ratio of -27.71 and a beta of -0.16. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.80 and a quick ratio of 16.80. The business has a fifty day moving average price of $45.88 and a 200-day moving average price of $41.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. On average, equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Institutional Trading of Akero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AKRO. Voya Investment Management LLC lifted its position in Akero Therapeutics by 302.9% in the first quarter. Voya Investment Management LLC now owns 82,471 shares of the company's stock valued at $3,338,000 after purchasing an additional 62,000 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Akero Therapeutics by 4.7% in the first quarter. Rhumbline Advisers now owns 110,687 shares of the company's stock worth $4,481,000 after purchasing an additional 5,001 shares during the last quarter. Strs Ohio purchased a new position in shares of Akero Therapeutics during the first quarter valued at approximately $510,000. Intech Investment Management LLC raised its holdings in Akero Therapeutics by 54.4% in the 1st quarter. Intech Investment Management LLC now owns 58,522 shares of the company's stock worth $2,369,000 after purchasing an additional 20,620 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Akero Therapeutics by 53.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company's stock worth $4,449,000 after buying an additional 38,458 shares during the period.

Analysts Set New Price Targets

AKRO has been the subject of a number of recent research reports. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. HC Wainwright boosted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Bank of America boosted their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Finally, Citigroup cut their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.